Omalizumab treatment in patient with severe asthma and Eosinophilic Granulomatosis with Polyangiitis . A case report.
Eosinophilic Granulomatosis with Polyangiitis (EGPA), formerly named Churg Strauss Syndrome, is a multisystem disorder characterized by chronic rhinosinusitis, asthma, and prominent peripheral blood eosinophilia; it is classified as a vasculitis of the small and medium sized arteries, although the vasculitis is often not clinically apparent in the initial phases of the disease. We present the case of a woman with EGPA who was frequently treated with high dose steroid therapy during hospital admission for refractory asthma. After December 2008, the date when we started Omalizumab, we observed a significative reduction of circulating eosinophils and IgE serum level, and the patient was no more hospitalized for respiratory failure or asthma attacks.
UO Medicina Interna, Ospedale degli Infermi, Faenza, Italy - AUSL Ravenna Phone: +39 054 660 12 14 E-mail: alessandro.graziani@ausl.ra.it.
A
A
Graziani
Ambulatorio Alta Specializzazione in Allergologia, Ospedale degli Infermi, Faenza, Italia.
O
O
Quercia
Servizio di Reumatologia Ospedale GB Morgagni, Forlì, Italia.
F
F
Girelli
UO Medicina Interna, Ospedale degli Infermi, Faenza, Italia.
A
A
Martelli
UO Medicina Interna, Ospedale degli Infermi, Faenza, Italia.
F
F
Mirici Cappa
UO Medicina Interna, Ospedale degli Infermi, Faenza, Italia.
G F
GF
Stefanini
D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D015267:Churg-Strauss Syndrome / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D008875:Middle Aged; D000069444:Omalizumab
D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab; D007073:Immunoglobulin E
Asthma; Eosinophilic Granulomatosis with Polyangiitis (EGPA); Omalizumab; eosinophilia